Oct 19, 2020
Neurodegenerative diseases affect millions of people worldwide. And with the world demographics getting older, it is apt to foretell that the burden of neurodegenerative disorders is expected to mount. With advances in medical technology, the life expectancy of people has drastically increased, reeling people to an...
Read More...
Jun 17, 2020
50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...
Read More...
Oct 23, 2019
Not a long time ago this year, Biogen announced the halting of Phase III clinical trials, EMERGE and ENAGE, of its most looked upon drug aducanumab under simulations for the treatment of Alzheimer's disease called futility analysis. The drug was designed to help patients struggling with mild cognitive impairmen...
Read More...
Sep 21, 2019
World Alzheimer’s Day World Alzheimer’s Day takes place on 21 September of every year. World Alzheimer's Day is a campaign to raise awareness and highlight issues faced by people those who are affected by dementia. The exact cause of Alzheimer's disease is not known, although several things are considered to ...
Read More...
Jun 05, 2019
Dementia is an umbrella term, usually of a chronic or progressive nature, causing deterioration in cognitive function. Associated with memory loss and decline other in other thinking skills, it is just not restricted to that. Problems with language, decision making, judgement, abstract thinking, struggling in takin...
Read More...
May 02, 2019
EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...
Read More...
Mar 27, 2019
Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum. But for more than two decades now Scientists from everywhere have been working on the “amyloid hypothesis". It has been a long-standing theory that brains of the people affected ...
Read More...
Mar 25, 2019
What is Epilepsy? Epilepsy is a neurological disorder which mainly affects the central nervous system. It is a chronic and non-communicable disorder associated with unpredictable seizures which affect the body and can result in injuries hence is a physical condition too. Anyone can develop Epilepsy at any a...
Read More...
Dec 21, 2018
Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equ...
Read More...
Dec 18, 2018
HER2 Vaccine Candidate Meet Phase 1b Study An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, successfully finished its phase 1b clinical trial and head to a phase 2 study. The first tranche of data from the 14-patient trial comes...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper